4,093
Views
1
CrossRef citations to date
0
Altmetric
Original Article

A novel intragastric balloon for treatment of obesity and type 2 diabetes. A two-center pilot trial

ORCID Icon, , , , , , , , , , , , & show all
Pages 232-238 | Received 17 Sep 2021, Accepted 11 Oct 2021, Published online: 29 Oct 2021

References

  • World Health Organization. Obesity and overweight [Internet]. Geneva (Switzerland): WHO; 2020. Available from: https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight
  • Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381(25):2440–2450.
  • Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377(9765):557–567.
  • Fildes A, Charlton J, Rudisill C, et al. Probability of an obese person attaining normal body weight: cohort study using electronic health records. Am J Public Health. 2015;105(9):e54–e59.
  • Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes – 5-year outcomes. N Engl J Med. 2017;376(7):641–651.
  • Nguyen NT, Varela JE. Bariatric surgery for obesity and metabolic disorders: state of the art. Nat Rev Gastroenterol Hepatol. 2017;14(3):160–169.
  • Flum DR, Khan TV, Dellinger EP. Toward the rational and equitable use of bariatric surgery. JAMA. 2007;298(12):1442–1444.
  • Jakobsen G, Småstuen M, Sandbu R, et al. Association of bariatric surgery vs medical obesity treatment with long-term medical complications and obesity-related comorbidities. JAMA. 2018;319(3):291–301.
  • Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
  • Cefalu WT, Bray GA, Home PD, et al. Advances in the science, treatment, and prevention of the disease of obesity: reflections from a diabetes care editors’ expert forum. Diabetes Care. 2015;38(8):1567–1582.
  • Kotinda A, de Moura DTH, Ribeiro IB, et al. Efficacy of intragastric balloons for weight loss in overweight and obese adults: a systematic review and meta-analysis of randomized controlled trials. Obes Surg. 2020;30(7):2743–2753.
  • Genco A, Ernesti I, Ienca R, et al. Safety and efficacy of a new swallowable intragastric balloon not needing endoscopy: early Italian experience. Obes Surg. 2017;28(2):40.
  • Raftopoulos I, Giannakou A. The elipse balloon, a swallowable gastric balloon for weight loss not requiring sedation, anesthesia or endoscopy: a pilot study with 12-month outcomes. Surg Obes Relat Dis. 2017;13(7):1174–1182.
  • Machytka E, Gaur S, Chuttani R, et al. Elipse, the first procedureless gastric balloon for weight loss: a prospective, observational, open-label, multicenter study. Endoscopy. 2017;49(2):154–160.
  • Machytka E, Chuttani R, Bojkova M, et al. Elipse™, a procedureless gastric balloon for weight loss: a proof-of-concept pilot study. Obes Surg. 2016;26(3):512–516.
  • Chuttani R, Machytka E, Raftopoulos I, et al. The first procedureless gastric balloon for weight loss: final results from a multi-center, prospective study evaluating safety, efficacy, metabolic parameters, quality of life, and 6-month follow-up. Gastroenterology. 2016;150(4):S26.
  • Al-Subaie S, Khalifa S, Buhaimed W, et al. A prospective pilot study of the efficacy and safety of elipse intragastric balloon: a single-center, single-surgeon experience. Int J Surg. 2017;48:16–22.
  • Alsabah S, Al Haddad E, Ekrouf S, et al. The safety and efficacy of the procedureless intragastric balloon. Surg Obes Relat Dis. 2018;14(3):311–317.
  • Ienca R, Al Jarallah M, Caballero A, et al. The procedureless elipse gastric balloon program: multicenter experience in 1770 consecutive patients. Obes Surg. 2020;30(9):3354–3362.
  • Ramai D, Singh J, Mohan BP, et al. Influence of the elipse intragastric balloon on obesity and metabolic profile: a systematic review and meta-analysis. J Clin Gastroenterol. 2020;55(10):836–841. Publish Ahead of Print.
  • Crea N, Pata G, Della Casa D, et al. Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg. 2009;19(8):1084–1088.
  • Popov VB, Ou A, Schulman AR, et al. The impact of intragastric balloons on obesity-related co-morbidities: a systematic review and meta-analysis. Am J Gastroenterol. 2017;112(3):429–439.
  • Norwegian Directorate of Health. Prevention, assessment and treatment of overweight and obesity in adults. National guidelines for primary health care. (IS-1753 Forebygging, utredning og behandling av overvekt og fedme hos voksne. Nasjonale retningslinjer for primærhelsetjenesten).
  • Perri F, Pastore MR, Annese V. 13C-octanoic acid breath test for measuring gastric emptying of solids. Eur Rev Med Pharmacol Sci. 2005;9(5):3–8.
  • Ghoos YF, Maes BD, Geypens BJ, et al. Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology. 1993;104(6):1640–1647.
  • Gómez V, Woodman G, Abu Dayyeh BK. Delayed gastric emptying as a proposed mechanism of action during intragastric balloon therapy: results of a prospective study. Obesity. 2016;24(9):1849–1853.
  • Lopez-Nava G, Asokkumar R, Rull A, et al. Bariatric endoscopy procedure type or follow-up: what predicted success at 1 year in 962 obese patients? Endosc Int Open. 2019;07(12): E1691–E1698.